Rising Demand For Gene Therapy Driving The Growth Of The Market Due To Advancements In Biotechnology And Targeted Treatments: A Significant Driver Propelling The Fatty Acid Oxidation Disorders (FAODs) Market In 2025

The Fatty Acid Oxidation Disorders (FAODs) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Fatty Acid Oxidation Disorders (FAODs) Market Size and Projected Growth Rate?
Recent years have seen a robust expansion in the market size for fatty acid oxidation disorders (FAODs). The market, which stood at $9.55 billion in 2024, is projected to escalate to $10.33 billion in 2025, registering a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historic period include enhanced awareness, an upward trend in the prevalence of rare and genetic disorders, an increase in product approvals, amplified governmental initiatives, and a growing demand for orphan drugs.

Anticipated to see robust expansion in the coming years, the market size for fatty acid oxidation disorders (FAODs) is projected to reach $13.99 billion in 2029, with a compound annual growth rate (CAGR) of 7.9%. This vigorous growth during the forecast period can be ascribed to the escalated demand for sustainable bio-products, the rising implementation of personalized healthcare, early FAODS diagnosis, increased R&D funding, and an elevated focus on enhancing long-term results. The upcoming period is expected to witness key trends such as the incorporation of telehealth services, the utilization of artificial intelligence in diagnostics and drug development, progress in genetic testing, technology advancements, and a transition towards patient-oriented care models.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21964

What Are the Major Segments in the Fatty Acid Oxidation Disorders (FAODs) Market?
The fatty acid oxidation disorders (FAODs) market covered in this report is segmented -

1) By Type: Long Chain, Short Chain
2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types
3) By Route of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores
5) By End User: Hospitals, Clinics, Pharmaceutical Companies

Subsegments:

1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21964&type=smp

What Are The Driving Fatty Acid Oxidation Disorders (FAODs) Market Evolution?
The growth of the fatty acid oxidation disorders (FAODs) market is anticipated to be fueled by the escalating demand for gene therapy. Gene therapy is a medical approach that aims to manipulate or substitute faulty genes to treat or prevent diseases. The surge in demand for this therapy is due to its ability to address genetic disorders, cancer, and rare diseases by targeting the genetic causes, in turn, prompting notable investment and progress in biotechnology. In treating FAODs, gene therapy strives to rectify metabolic deficiencies by introducing functional genes to restore enzymatic function, boost energy production, and avert disease complications. Notably, in April 2024, the American Society of Gene & Cell Therapy - a US-based institution dedicated to gene and cell therapy, reported a 10% rise in the number of gene therapies undergoing Phase III clinical trials in the fourth quarter. This marks the inaugural quarterly growth of this sort since Q3 of 2022. Consequently, the burgeoning demand for gene therapy is bolstering the expansion of the fatty acid oxidation disorders (FAODs) market.

Which Firms Dominate The Fatty Acid Oxidation Disorders (FAODs) Market Segments?
Major companies operating in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Frères SA, Dr Reddy's Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, NB Group Co Ltd.

What Trends Are Expected to Dominate the Fatty Acid Oxidation Disorders (FAODs) Market in the Next 5 Years?
Leading industry players in the fatty acid oxidation disorders (FAODs) market are concentrating on developing groundbreaking treatments like peroxisome proliferator-activated receptor delta (PPARδ) agonists. These advances may increase metabolic control and improve the prognosis for patients with FAODs. PPARδ agonists are compounds that activate the PPARδ receptor, which plays a vital role in the regulation of lipid metabolism, inflammation, and energy balance. These agonists could offer beneficial effects for metabolic and cardiovascular conditions. For example, in January 2023, the US-based clinical-stage pharmaceutical corporation, Reneo Pharmaceuticals Inc., was granted Fast Track status by the U.S. Food and Drug Administration (FDA) for its trial drug, Mavodelpar (REN001). The drug is aimed at tackling the long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype linked with long-chain fatty acid oxidation disorder (LC-FAOD). With the activation of PPARδ, Mavodelpar is intended to improve mitochondrial function, enhance energy metabolism, and alleviate LC-FAOD-related symptoms.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/fatty-acid-oxidation-disorders-faods-global-market-report

Which Is The Largest Region In The Fatty Acid Oxidation Disorders (FAODs) Market?
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in the fatty acid oxidation disorders (FAODs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Fatty Acid Oxidation Disorders (FAODs) Market?
2. What is the CAGR expected in the Fatty Acid Oxidation Disorders (FAODs) Market?
3. What Are the Key Innovations Transforming the Fatty Acid Oxidation Disorders (FAODs) Industry?
4. Which Region Is Leading the Fatty Acid Oxidation Disorders (FAODs) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.